DIA 2013 49th Annual Meeting to Address Hot Topics Surrounding Patient
Sessions to Highlight Patient Voices, Alzheimer’s, Big Data
HORSHAM, Pa. -- April 3, 2013
The DIA 2013 49th Annual Meeting, to be held June 23–27 at the Boston
Convention & Exhibition Center, will feature 22 tracks and more than 250
educational offerings, including sessions addressing urgent issues surrounding
patient advocacy, big data and Alzheimer’s. These sessions, along with a large
number of panels, forums and networking opportunities, aim to foster
collaboration and drive conversation between patients and key industry and
regulatory professionals to advance the development and regulation of safe and
effective medical products.
Big Data: Impact on Innovation, June 25, 10:15 a.m.—Susan Dentzer,
editor-in-chief of the leading peer-reviewed medical journal Health Affairs,
will chair this discussion about how data are being used to support safety and
efficiency, about how data affect the payer landscape, and to share best
practices. Dentzer will be joined by keynote speaker Michael Rosenblatt, chief
medical officer of Merck & Co., along with an esteemed panel of experts
representing the pharmaceutical industry, regulatory affairs, clinical
research and patient perspectives.
Advancing Alzheimer’s Innovation, June 26—A variety of sessions will focus on
advancing care in Alzheimer’s disease, bringing together representatives from
the patient advocacy and industry communities.
*A Call to Action, 10:15 a.m.—Meryl Comer, president of the Geoffrey Beene
Foundation, will chair this discussion about the global impact of
Alzheimer’s and the progress toward earlier detection, along with key
steps being taken to address the growing epidemic.
*Patient Advocacy, Caregiver Support and Health Care System Impact, 1:45
p.m.—Leaders from Sanofi and the Alliance for Aging Research will discuss
how to foster collaboration to bridge the gap between industry and
regulators, and enhance clinical trials and data collection.
*Clinical Development Successes and Challenges, 4:00 p.m.—Top executives
from Eisai Inc. and Merck & Co., and leading researchers from
Massachusetts Alzheimer’s Disease Research Center, will discuss the
challenges encountered in early and late clinical development, lessons
learned from past trials and recommendations in trial design.
Patient Advocacy Panel, June 24, 10 a.m.—A panel of current fellows and alumni
from the DIA Patient Advocate Fellowship Program will share inspiring stories
of advancing patient engagement through their organizations. Patients and
advocates will discuss how organizations can take vital steps to improve
development of treatment, such as setting up registries to collect patient
data, educating patients on diseases, working hand in hand with clinicians and
researchers, identifying and boosting attendance for clinical trials and
navigating the pharmaceutical industry and regulation to advance the
development of treatment for diseases, especially in cases in which no
treatment yet exists.
For more information, visit www.diahome.org.
DIA is a neutral, global, professional, member-driven association of nearly
18,000 professionals involved in the discovery, development and life cycle
management of pharmaceuticals, biotechnology, medical devices and related
medical products. Through our international educational offerings and myriad
networking opportunities, DIA provides a global forum for knowledge exchange
that fosters the innovation of products, technologies and services to improve
health and well-being worldwide. Headquarters are in Horsham, Pa., with
offices in Basel, Switzerland; Tokyo; Mumbai, India; and Beijing.
Eric Rosen, 215-290-9153
Press spacebar to pause and continue. Press esc to stop.